Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Analysis — Probabli.AI
AI-powered analysis for TNXP (Tonix Pharmaceuticals Holding Corp.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Neutral.
Last price: $13.98 · Market cap: $198.6M · AI consensus: Neutral
Tonix Pharmaceuticals represents a high-risk, high-reward investment in the volatile biotech space. While recent positive news improves the potential for upside scenarios, significant financial and operational risks persist. Future performance hinges on clinical trial success, regulatory approvals, and the ability to secure non-dilutive funding.
Probabilistic 1-Year Outlook
- Bull 4000% · Neutral 3500% · Bear 2500%
- Tonix Pharmaceuticals has a volatile profile driven by its developmental pipeline and recent positive news; however, its high cash burn rate and recent trial failures pose significant risks.
5-Year Outlook
- Bull 5000% · Neutral 3000% · Bear 2000%
SWOT Highlights
- Strength: Innovative pharmaceutical pipeline
- Strength: Recent positive trial results for PTSD treatment
- Risk: Consistent financial losses
- Risk: Analyst mean and median price targets are lower than current price
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
4 Wall Street analysts rate TNXP a HOLD with a mean price target of $2.
Analysis generated Apr 20, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/TNXP.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.